Marion Odence-Ford sold $61k of OPRX
General Counsel and CCO at OptimizeRx Corp. 4,000 shares at an average of $15.19, traded Jan 9, 2024, filed Jan 11, 2024.
Score components
- +15RoleOfficer
- +7Trade size$61k at market
- +10Share of holdings soldSold 26% of holdings
- 0ClusterNo other insider selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001628280-24-001190, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 9, 2024 | SOpen-market sale Common Stock10b5-1 | -4,000 | $15.19 | $61k | 11,114 | Jan 11, 2024 |
Related signals
Other insiders at OptimizeRx Corp and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 7Weak | OPRXsell OptimizeRx Corp | Edward Stelmakh Chief Finance & Strat Officer | $19k 1,388 shares | -1% | |
| 15Weak | OPRXsell OptimizeRx Corp | Stephen L Silvestro Chief Executive Officer | $30k 1,620 shares | -1% | |
| 32Weak | OPRXsell OptimizeRx Corp | Patrick D Spangler director | $194k 11,120 shares | -20% | |
| 35Weak | OPRXbuy OptimizeRx Corp | William J Febbo CEO | $100k 20,000 shares | +3% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.